Seres Therapeutics (NASDAQ:MCRB) Given Buy Rating at Chardan Capital
Chardan Capital reissued their buy rating on shares of Seres Therapeutics (NASDAQ:MCRB – Free Report) in a report issued on Wednesday, Benzinga reports. They currently have a $1.25 price target on the biotechnology company’s stock. Chardan Capital also issued estimates for Seres Therapeutics’ FY2025 earnings at ($0.82) EPS. A number of other brokerages also recently […]
More Stories
Croda International (OTCMKTS:COIHD) Sets New 1-Year Low – Time to Sell?
Croda International Plc (OTCMKTS:COIHD – Get Free Report)’s share price reached a new 52-week low on Tuesday . The stock...
iShares ESG Aware MSCI EAFE ETF (NASDAQ:ESGD) Short Interest Update
iShares ESG Aware MSCI EAFE ETF (NASDAQ:ESGD – Get Free Report) was the recipient of a significant increase in short...
Earlyworks Co., Ltd (NASDAQ:ELWS) Short Interest Update
Earlyworks Co., Ltd (NASDAQ:ELWS – Get Free Report) saw a significant increase in short interest during the month of October....
SSP Group (OTCMKTS:SSPPF) Sets New 12-Month High – What’s Next?
Shares of SSP Group plc (OTCMKTS:SSPPF – Get Free Report) hit a new 52-week high during mid-day trading on Tuesday...
Hays (OTCMKTS:HAYPY) Hits New 12-Month Low – Here’s What Happened
Hays plc (OTCMKTS:HAYPY – Get Free Report)’s stock price hit a new 52-week low during mid-day trading on Tuesday ....
Rocket Internet (FRA:RKET) Shares Up ∞ – Here’s Why
Rocket Internet SE (FRA:RKET – Get Free Report) traded up ∞ on Tuesday . The company traded as high as...